NCEL Stock Forecast: NewCelX Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.54
−5.58% on the day

The median 12-month analyst price target for NewCelX Ltd. is $23. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$14.7M
Ticker Nerd rank
4/ 100
Median analyst target
$23
Analysts covering
1
Total return, dividends reinvested
1W
−2.7%
1M
−2.7%
YTD
+33.7%
1Y
−19.4%
From 52W high
−48.3%
From 52W low
+35.1%
$1.88
$4.91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores NewCelX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
4/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
48
Revisions
20
Growth
10
Momentum
10
Value
10
Issuance
6
Quality
5
Accruals
5

Volatility (48): The share price has been relatively steady.

Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NCEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NCEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26NCELHigh $23Median $23Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$23
Low
$23
Median
$23
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026Laidlaw & Co.InitiatesBuy$23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NCEL.

Market Radar

This page is one stock. Monday covers all of them.

NCEL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NCEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, NewCelX Ltd. returned −19.4% against +6.9% for the S&P 500, dividends included.

NCEL vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26NCELS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NCEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.9×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
2.3×

Cheaper than 40% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−114.5%

Higher than 12% of US stocks

Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NewCelX Ltd. has a market value of $14.7M and an enterprise value of $13.4M.

  • Shares outstanding: 4.8M.

  • Trailing P/E: 4.9×.

  • NewCelX Ltd. employs 9 people.

market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

NCEL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NCELNewCelX Ltd.$14.7M4
ACTUActuate Therapeutics, Inc.$13.6M39
PLURPluri, Inc.$13.5M17
ESLAEstrella Immunopharma, Inc.$13.5M26
BYSIBeyondSpring, Inc.$13.7M11
ABOSAcumen Pharmaceuticals, Inc.$13.5M42
CTXRCitius Pharmaceuticals, Inc.$14.0M34

Take a look at NCEL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own NewCelX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NCEL

What is the NCEL stock price forecast for 2026-2027?

The median 12-month analyst price target for NewCelX Ltd. is $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NCEL stock a buy right now?

Of the 1 analyst covering NewCelX Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NewCelX Ltd. 4 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NCEL?

As at 21 Nov 2026, NewCelX Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (48 of 100).

Will NCEL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $23, and Ticker Nerd's factor model ranks NewCelX Ltd. 4 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NCEL stock forecast for 2030?

No analyst covering NewCelX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $23 over the next 12 months.

How has NCEL stock performed over the past year?

NewCelX Ltd. returned -19.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NewCelX Ltd. do?

NewcelX Ltd. is a Switzerland-based biopharmaceutical company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Its current portfolio centers on stem-cell-derived and off-the-shelf regenerative medicine programs, including therapies for Type 1 diabetes, insulin-dependent Type 2 diabetes, amyotrophic lateral sclerosis, and other neurological conditions.

Company

About NewCelX Ltd.

NewcelX Ltd. is a Switzerland-based biopharmaceutical company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Its current portfolio centers on stem-cell-derived and off-the-shelf regenerative medicine programs, including therapies for Type 1 diabetes, insulin-dependent Type 2 diabetes, amyotrophic lateral sclerosis, and other neurological conditions. The company’s work combines cell replacement, neuroscience, and translational research to address areas with significant unmet medical need. NewcelX Ltd. also develops a dual orexin-receptor agonist platform for sleep disorders and related neurological indications, reflecting a broader approach across metabolic, inflammatory, and central nervous system disorders. Headquartered in Kloten, Switzerland, NewcelX Ltd. operates as a clinical-stage biotechnology firm with research and development activities supporting its therapeutic pipeline.

CEO Mr. Ronen Twito CPA · 9 employees · Switzerland · https://newcelx.com